Fig. 1: Participant flow in the SCORES trial. | Nature Cancer

Fig. 1: Participant flow in the SCORES trial.

From: Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial

Fig. 1

aParticipants were randomized in a 2:1 ratio and stratified according to platinum-refractory status (yes versus no), number of prior systemic therapies (one versus two), chemotherapeutic agent (paclitaxel versus PEGylated liposomal doxorubicin versus topotecan) and prior antiangiogenic therapy (yes versus no). More information is provided in the Table 1 footnotes. For the safety analysis, one participant who was randomized but did not receive planned treatment was excluded.

Back to article page